A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

Published:2018-02 Issue:2 Volume:13 Page:273-279
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hotta Katsuyuki,Aoe Keisuke,Kozuki Toshiyuki,Ohashi Kadoaki,Ninomiya Kiichiro,Ichihara Eiki,Kubo Toshio,Ninomiya Takashi,Chikamori Kenichi,Harada Daijiro,Nogami Naoyuki,Hirata Taizo,Hinotsu Shiro,Toyooka Shinichi,Kiura Katsuyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference12 articles.

1. Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled into phase III trials of first-line systemic chemotherapy;Hotta;Cancer,2007

2. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials;Hotta;Ann Oncol,2004

3. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer;Kuyama;J Thorac Oncol,2008

4. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives;Mazières;J Clin Oncol,2013

5. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate;Lewis Phillips;Cancer Res,2008

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review;ecancermedicalscience;2024-08-01

2. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

3. HER2-Mutant Advanced and/or Metastatic Non–Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes;Clinical Lung Cancer;2024-06

4. Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors;Expert Opinion on Pharmacotherapy;2024-05-23

5. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers;BioDrugs;2024-05-20